U.S. Energy Boom Ke...
Health Care: Drugs
Dyax Corporation (DYAX: NASDAQ)
$2.62 0.09 | 3.56%
05/23/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 20.02M | 31.47M | 18.60M | 29.39M |
| Receivables | 7.51M | 6.09M | 5.32M | 2.72M |
| Inventories | 4.08M | 7.02M | 1.70M | 578.00K |
| Other Current Assets | 2.16M | 4.97M | 2.90M | 2.82M |
| Total Current Assets | 42.80M | 76.85M | 88.56M | 58.51M |
| Property, Plant & Equipment, Gross | 18.71M | 25.45M | 21.24M | 21.13M |
| Accumulated Depreciation & Depletion | 13.38M | 20.57M | 19.06M | 17.63M |
| Property, Plant & Equipment, Net | 5.33M | 4.88M | 2.18M | 3.51M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 7.36M | 1.64M | 1.69M | 2.78M |
| Total Non-Current Assets | 12.69M | 6.52M | 3.87M | 6.29M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 55.49M | 83.38M | 92.43M | 64.80M |
| Accounts Payable | 3.56M | 2.93M | 1.40M | 11.79M |
| Short Term Debt | 445.00K | 101.00K | 586.00K | 890.00K |
| Other Current Liabilities | 0.00 | 1.71M | 700.00K | 1.36M |
| Total Current Liabilities | 18.37M | 23.76M | 20.70M | 24.39M |
| Long Term Debt | 78.06M | 75.37M | 56.41M | 58.75M |
| Deferred Income Taxes | 3.29M | 2.37M | 30.00K | 0.00 |
| Other Non-Current Liabilities | 7.33M | 9.26M | 12.67M | 20.27M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 88.68M | 87.01M | 69.10M | 79.02M |
| Total Liabilities | 107.05M | 110.77M | 89.80M | 103.40M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | -51.56M | -27.40M | 2.63M | -38.60M |
| Common Par | 995.00K | 988.00K | 985.00K | 781.00K |
| Additional Paid In Capital | 453.62M | 448.53M | 443.93M | 378.42M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -506.19M | -476.92M | -442.32M | -417.82M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 6.00K | 7.00K | 44.00K | 15.00K |
| Total Capitalization | 26.50M | 47.97M | 59.04M | 20.15M |
| Total Equity | -51.56M | -27.40M | 2.63M | -38.60M |
| Total Liabilities & Stock Equity | 55.49M | 83.38M | 92.43M | 64.80M |
| Total Common Shares Outstanding | 99.48M | 98.80M | 98.51M | 78.07M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 98.99M | 98.73M | 93.27M | 69.15M |
| Diluted Weighted Shares Outstanding | 98.99M | 98.73M | 93.27M | 69.15M |
| Number of Employees | 125 | 120 | 137 | 121 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with DYAX
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- UserSUPRATRADE-0303071618
- Userdulcinea
- ContributorOptions Action Portfolio Fe...
- UserLast Day of the JPMorgan He...
- UserBarron's Research Reports 7...
- UserPART 6 JPMorgan 26th Annual...
- Userpnp.v
- UserSpec #1
- Userjan's specs
Latest DYAX Headlines from TheStreet
- 5 Biotech Stocks Poised for Breakouts 07.27.12 | 01:07 pm
- Dyax Corporation CEO Discusses Q2 2012 Results - Earnings Call Transcript 07.19.12 | 08:07 pm
- Dyax's CEO Presents At Deutsche Bank AG Health Care Conference (Transcript) 05.07.12 | 03:05 pm
- Dyax Stock Gaps Down On Today's Open (DYAX) 07.19.11 | 09:07 am
- Dyax Corporation CEO Discusses Q3 2010 Results - Earnings Call Transcript 10.28.10 | 03:10 am
- Dyax Corp. Q2 2010 Earnings Call Transcript 07.28.10 | 10:07 pm
- Merck Buys British Maker Of Biotech Medicines 12.17.09 | 12:12 pm
- Cubist Stops Enrollment In Anti-bleeding Studies 12.03.09 | 01:12 pm
- Delta, Walgreen, Diedrich Coffee Are Big Movers 12.02.09 | 04:12 pm
- Dyax Shares Rocket On FDA Clearance For Kalbitor 12.02.09 | 11:12 am
Press Releases for DYAX
- Dyax Corp. To Participate In The 25th Annual ROTH Conference - Business Wire 03.12.13 | 07:03 am
- Dyax Announces Management Change - Business Wire 03.08.13 | 08:03 am
- Dyax Presents DX-2930 Data At The 2013 American Academy Of Allergy, Asthma And Immunology Annual Meeting - Business Wire 02.25.13 | 07:02 am
- Dyax Corp. To Participate In Upcoming 2013 Healthcare Conferences - Business Wire 02.20.13 | 07:02 am
- Dyax Corp. Announces Fourth Quarter And Full Year 2012 Financial Results - Business Wire 02.13.13 | 04:02 pm
- Dyax Corp. And CVie Therapeutics Announce Partnership To Develop And Commercialize KALBITOR® (ecallantide) For Hereditary Angioedema (HAE) And Other Angioedema Indications In China, Hong Kong And Macau - Business Wire 02.07.13 | 07:02 am
- Dyax Corp. To Participate In The Leerink Swann Global Healthcare Conference - Business Wire 02.06.13 | 07:02 am
- Dyax Corp. To Host Fourth Quarter And Year End 2012 Earnings Call And Webcast - Business Wire 02.05.13 | 07:02 am
- Dyax Corp. And Novellus Biopharma AG Announce Partnership To Develop And Commercialize KALBITOR® (ecallantide) For Hereditary Angioedema (HAE) And Other Angioedema Indications In Latin America - Business Wire 01.31.13 | 07:01 am
- Behind The Success - Research Report On Corcept Therapeutics Inc. And Dyax Corp. - PR Newswire 01.23.13 | 08:01 am
Partner Headlines for DYAX
- Microvision CRASHES 24% to Lead 3 NASDAQ Top Percentage Losers - Wall St. Cheat Sheet 06.18.12 | 09:06 am
- Barclays UPGRADES Dollar General to Overweight and 4 Stocks on Analyst Radars - Wall St. Cheat Sheet 06.15.12 | 04:06 am
- Morning Market Losers - Benzinga 07.19.11 | 09:07 am
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 07.13.11 | 09:07 am
- Low-Priced Biotech Stocks With Insider Buying - Seeking Alpha 03.18.11 | 06:03 pm
- Dyax Corp. Hits New 52-Week Low (DYAX) - Benzinga 01.04.11 | 09:01 am
- UPDATE 1-Dyax, Sigma-Tau agree to develop, market genetic drug - Reuters 06.21.10 | 08:06 am
- CORRECTED - CORRECTED-UPDATE 1-Dyax posts narrower-than-expected Q4 loss - Reuters 02.17.10 | 09:02 am
